The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β-catenin signaling axis

Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab. The addition of celecoxib augmented the efficacy of cetuximab to inhibit cell proliferation and to induce apoptosis in CRC cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Valverde, Araceli, Peñarando, Jon, Cañas, Amanda, López-Sánchez, Laura M., Conde, Francisco, Guil-Luna, Silvia, Hernández, Vanessa, Villar, Carlos, Morales-Estévez, Cristina, de la Haba-Rodríguez, Juan, Arand o, Enrique, Rodríguez-Ariza, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400621/
https://www.ncbi.nlm.nih.gov/pubmed/28423516
http://dx.doi.org/10.18632/oncotarget.15567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400621/
https://www.ncbi.nlm.nih.gov/pubmed/28423516
http://dx.doi.org/10.18632/oncotarget.15567

Ejemplares similares